Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00306202 · OUTCOME

Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia · Source last updated 2021-02-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
At baseline (within 3 weeks before initiation of study therapy)

What was measured

FLT3 and KIT = These are fused genes found in participants with this type of leukemia.

Analysis population: All treated participants in stratum 4: Participants who received at least 1 dose of study therapy.

Groups in this outcome

Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose

Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose24

Reported measurements

FLT3 Absent
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose20Not reportedNot reportedNot reportedNot reported
FLT3 Present
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose1Not reportedNot reportedNot reportedNot reported
FLT3 No Data
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose3Not reportedNot reportedNot reportedNot reported
KIT Absent
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose21Not reportedNot reportedNot reportedNot reported
KIT Present
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose0Not reportedNot reportedNot reportedNot reported
KIT No Data
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        20
    title
    FLT3 Absent
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    FLT3 Present
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    FLT3 No Data
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        21
    title
    KIT Absent
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    KIT Present
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    KIT No Data
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
FLT3 and KIT = These are fused genes found in participants with this type of leukemia.
groups
  1. description
    Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.
    id
    OG000
    title
    Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose
param Type
NUMBER
population Description
All treated participants in stratum 4: Participants who received at least 1 dose of study therapy.
reporting Status
POSTED
time Frame
At baseline (within 3 weeks before initiation of study therapy)
title
Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice